MRK

SEC source: 0001127602-22-010797 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,460.6913

Underlying: Common Stock · 365.6307 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-006996 · form4.xml · nonDerivative · entry 1

Davis Robert M · CIK 0001363076 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,592.757

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007002 · form4.xml · nonDerivative · entry 1

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,896.542

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007000 · form4.xml · nonDerivative · entry 1

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,981.357

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007005 · form4.xml · nonDerivative · entry 1

FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 706,283.063

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007008 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,712.138

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007013 · form4.xml · nonDerivative · entry 1

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,276.972

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007016 · form4.xml · nonDerivative · entry 1

Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,058.93

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007019 · form4.xml · nonDerivative · entry 1

Li Dean Y · CIK 0001837016 · Executive VP & President, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,462.118

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007023 · form4.xml · nonDerivative · entry 1

Litchfield Caroline · CIK 0001854928 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,555.8061

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007025 · form4.xml · nonDerivative · entry 1

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,144.145

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007028 · form4.xml · nonDerivative · entry 1

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,603.757

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-007033 · form4.xml · nonDerivative · entry 1

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,419.167

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-004674 · form4.xml · derivative · entry 3

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,205

Underlying: Common Stock · 1,202 shares

Expires 2023-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/10/2021, 2/10/2022 and 2/10/2023.

F3 · derivative.underlying_shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-22-004674 · form4.xml · nonDerivative · entry 2

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,943.757

F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-004674 · form4.xml · nonDerivative · entry 1

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,420.757

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-000424 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,151.9136

Underlying: Common Stock · 391.4405 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-000437 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,894.3036

Underlying: Common Stock · 146.7902 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-000431 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,105.0003

Underlying: Common Stock · 212.0303 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-22-000447 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,841.9851

Underlying: Common Stock · 424.0605 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028802 · form4.xml · derivative · entry 5

FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 663,881 shares

Expires 2023-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.

F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028802 · form4.xml · nonDerivative · entry 3

FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 586,795.063

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.9500 to $83.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028802 · form4.xml · nonDerivative · entry 2

FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 616,410.063

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.9300 to $82.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-21-028802 · form4.xml · nonDerivative · entry 1

FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250,676.063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028467 · form4.xml · derivative · entry 3

Litchfield Caroline · CIK 0001854928 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,683 shares

Expires 2024-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2015, 5/2/2016 and 5/2/2017.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028467 · form4.xml · nonDerivative · entry 2

Litchfield Caroline · CIK 0001854928 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,113.7671

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.0000 to $91.0050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028467 · form4.xml · nonDerivative · entry 1

Litchfield Caroline · CIK 0001854928 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,448.7671

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028469 · form4.xml · derivative · entry 4

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,564

Underlying: Common Stock · 29,782 shares

Expires 2025-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.

F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028469 · form4.xml · nonDerivative · entry 2

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,929.963

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.0000 to $90.6700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028469 · form4.xml · nonDerivative · entry 1

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,711.963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028387 · form4.xml · derivative · entry 3

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,997

Underlying: Common Stock · 25,000 shares

Expires 2026-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028387 · form4.xml · nonDerivative · entry 2

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,798.972

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.4200 to $88.5400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028387 · form4.xml · nonDerivative · entry 1

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,798.972

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028169 · form4.xml · derivative · entry 9

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,848

Underlying: Common Stock · 19,847 shares

Expires 2024-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2015, 5/2/2016, and 5/2/2017.

F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028169 · form4.xml · derivative · entry 8

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,915 shares

Expires 2023-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F7 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.

F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 5

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,095.087

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.8000 to $87.8950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 4

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,857.087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 3

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,010.087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 9

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,831

Underlying: Common Stock · 11,414 shares

Expires 2030-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 8

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,698

Underlying: Common Stock · 19,394 shares

Expires 2029-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F6 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 7

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,175 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 6

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,287 shares

Expires 2027-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 5

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,162.138

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.9050 to $87.9250, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 4

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,432.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 3

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,018.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,624.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,449.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028163 · form4.xml · derivative · entry 3

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,715 shares

Expires 2021-10-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.

F3 · derivative.underlying_shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028163 · form4.xml · nonDerivative · entry 2

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,573.145

F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028163 · form4.xml · nonDerivative · entry 1

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,896.145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.